Business

May 9, 2014

Durham drug developer Chimerix posts 1Q loss

Durham antiviral drug developer Chimerix posts a 1Q loss as it moves forward with its lead drug, brincidofovir, which is being developed to counter fatal viruses and bioterror attacks.

Related content

Comments

Videos

Editor's Choice Videos